new RP-HPLC method for analysis of mebeverine hydrochloride in raw materials and tablets

A simple, sensitive, selective, reliable, least time consuming and rapid high-performance liquid chromatographic method for the determination and quantification of meheverine hydrochloride using hyoscine butylbromide as internal standard has been developed. The chromatographic system consisted of a Shimadzu LC-10 AT VP pump, SPD-10 AV VP UV visible detector, and a CBM-102 Bus Module integrator. Separation was achieved on the micro Bondapak 125 a C18 10 micro l column at room temperature. The samples were introduced through an injector valve with a 10 micro l sample loop. Acetonitrile-water [1:1 v/v] was used as mobile phase, with flow rate 1.7 ml/minutes. pH was adjusted to 2.9 with phosphoric acid. U.V detection was performed at 205 nm. The results obtained showed a good agreement with the declared content. Recovery values of mebeverine hydrochloride were from 99.80% to 100.13%. The proposed method is rapid, accurate, and selective and may be used for the quantitative analysis of mebeverine hydrochloride. The method was found to be specific, accurate, precise and reliable for the determination and quantification of mebeverine hydrochloride in form of raw materials, in bulk drugs and formulation. It was possible to determine all of them in the concentration range of 5-30 nano grams. The detection limit of mebeverine hydrochloride was 0.4-nano gram

Valoración clínica y endoscópica de la eficacia de cisaprida en comparación con metoclopramida en el reflujo gastroesofágico en niños / Clinical and endoscopic assessment of the efficacy of cisapride compared to metoclopramide in gastroesophageal reflux in children: multicenter study

Con objeto de conocer la frecuencia de enfermedad por reflujo gastroesofágico y su asociación con enfermedad pulmonar crónica, así como la respuesta al tratamiento, se estudiaron 23 pacientes mediante endoscopia a las 0 y ocho semanas de tratamiento con metoclopramida, o cosaprida bajo un diseño doble ciego. La evaluación clínica se efectuó cada dos semanas durante ocho semanas y se midió el tiempo de disminución o desaparición de la sintomatología. La patología respiratoria se presentó con una frecuencia mayor en relación 2:1. La sensibilidad diagnóstica de la endoscopia fue de 100 por ciento. De 12 pacientes tratados con cisaprida, nueve mejoraron clínica y endoscópicamente, al igual que dos pacientes con fracaso del otro tratamiento. En contraste, de 11 pacientes tratados con metoclopramida sólo seis mejoraron. La sintomatología desapareció más rapidamente con cisaprida. No se informaron efectos secundarios.

Ultrasonic study to see the effect of topical pilocarpine and homatropine on anterior chamber depth in phakic cases.

Pilocarpine and Homatropine are the drugs having known effect on the depth of anterior chamber. The purpose of this study was to demonstrate the time of onset, peak effect and its duration of action as well as shallowing/deepening of the anterior chamber, after single instillation of pilocarpine 2% or homatropine bromide 2%, topically in one eye. Also we tried to see if there is any effect on the contralateral eye, due to systemic absorption of pilocarpine, homatropine after topical instillation of the drug in one eye. Pilocarpine causes a measurable shallowing of the anterior chamber with onset of effect with in 20 minutes and a peak in 60 minutes, the average narrowing being 0.26 mm. (range 0.20-0.29 mm.). Homatropine has a measurable deepening effect on the anterior chamber, due to axial flattening of the lens because of cycloplegia, with a range of 0.33 to 0.36 mm. In 70% of the cases the effect passes away with in 24 hours., but in 30% it comes to normal in 48 hours.

Interaçäo medicamentosa em pneumologia / Drug interactions in pneumology

Como conseqüência do uso freqüente de medicaçäo simultânea podem advir tanto complicaçöes leves quanto reaçöes colaterais sérias e até fatais. A farmacologia tem progredido no sentido de permitir um melhor conhecimento da interaçäo das drogas, prevenindo a maioria destes efeitos adversos. Entretanto, a prevençäo é limitada, tendo em vista a discrepância entre o número de interaçöes publicadas e o número de possíveis combinaçöes de medicamentos em doentes